Oncology

Latest News

Top 5 Most-Read Oncology Content of 2024

December 25th 2024

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Most Popular Articles of 2024 in Evidence-Based Oncology

By Mary Caffrey

December 23rd 2024

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

April 21st 2016

What We're Reading: ACA Is Having a Positive Impact on Personal Finances

AJMC Staff

What we're reading, April 21, 2016: Congress keeps things moving on the fight against the opioid epidemic; new paper from the National Bureau of Economic Research finds Medicaid expansion has a broader societal impact; and Novartis faces stiff competition from generic version of Gleevec.

April 20th 2016

What Is Coming in Specialty Pharmacy? A Look at the Near-Term Drug Pipeline

Laura Joszt, MA

AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016 kicked off by delving into the near-term specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts.

April 20th 2016

Clinical Pathways Get an In-Depth Look in Evidence-Based Oncology

The growth of clinical pathways in cancer care brings opportunities to improve quality and control cost, but there are frustrations, too. Physicians want to retain some freedom and are pushing back against the administrative jungle from multiple payers, according to a special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.

April 20th 2016

Nivolumab OS Data Raise Hopes in Head and Neck Cancer

Surabhi Dangi-Garimella, PhD

An international study evaluating nivolumab in head and neck cancer has found that patients treated with the checkpoint inhibitor were twice as likely to be alive at 1 year after initiating treatment, compared with patients who were given standard chemotherapy.

April 20th 2016

Dr Steve Miller Highlights the Importance of Working Closely With Oncologists

Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.

April 19th 2016

Dr Steven Pearson Outlines Specialty Conditions Impacting Healthcare Spending

Steven D. Pearson, MD, president of the Institute for Clinical and Economic Review, discussed the specialty conditions that are having the biggest impact on overall healthcare expenditures and pharmaceutical spending.

April 19th 2016

The Future of Specialty Pharmacy: Where Do We Need to Go?

Laura Joszt, MA

The specialty pharmacy industry is unique in many ways, but the price growth for these drugs is no longer sustainable, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.

April 19th 2016

Companion Diagnostic Tests for Immunotherapy Could Be Switched

Surabhi Dangi-Garimella, PhD

A study presented at the ongoing annual meeting of the American Association for Cancer Research has confirmed that 3 commercially available diagnostic tests that measure the expression of the programmed death ligand 1 protein in non-small cell lung cancer could be interchanged.

April 19th 2016

The Healthcare System's Struggle With Oncology Care Pathways

Surabhi Dangi-Garimella, PhD

While clinical pathways can help standardize care, considering the multitude of options available for oncology care providers, there is significant push-back from providers as well.

April 19th 2016

Improved Health and Cost Savings Possible With 9vHPV Vaccine Against Cervical Cancer

Surabhi Dangi-Garimella, PhD

A cost-economic analysis by researchers at the Yale School of Public Health has found that switching to Gardasil-9, which protects against 9 oncogenic serotypes of the human papillomavirus, would provide improved health benefits at the same or lower societal cost.

April 18th 2016

Are Oncology Clinical Pathways a Value Framework in the Making?

Surabhi Dangi-Garimella, PhD

Evidence-Based Oncology invited a panel of experts who are experienced in the creation of oncology care pathways, use them in their practice, and have researched the development and implementation of care pathways, to exchange ideas on the topic.

April 18th 2016

Targeting Stem Cells in Multiple Myeloma Could Improve Outcomes

Surabhi Dangi-Garimella, PhD

Targeting cancer stem cells could have a much better impact on the outcome of patients with multiple myeloma being treated with standard chemotherapy, a new single-arm study by researchers at Johns Hopkins has found.

April 16th 2016

This Week in Managed Care: April 16, 2016

April 16th 2016

Clinical Pathways: A Systems Approach Toward More Patient-Centric Cancer Care Delivery

Joseph Alvarnas, MD

Despite the fundamental advances in cancer care technology and care delivery that have made these improvements possible, our delivery system remains quite inefficient and frequently falls short of being truly patient-centered. Is a system-based solution the answer?

April 15th 2016

Dr Lucio Gordan Highlights Challenges Facing Oncologists in 2016

The biggest challenge facing oncologists in 2016 is the Medicare Part B demonstration that CMS announced, Lucio Gordan, MD, of Florida Cancer Specialists, said at the Community Oncology Alliance's 2016 Community Oncology Conference.

April 15th 2016

Industry Insight on the Challenges With Developing and Adopting Biosimilars

Surabhi Dangi-Garimella, PhD

Pharmaceutical industry experts provide an overview of the highly complex biosimilar development process at The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida.

April 15th 2016

Developing an Oncology Clinical Pathways Program - the UPMC Case Study

Peter G. Ellis, MD

An overview of the oncology clinical pathways development program at the UPMC CancerCenter and how it led to the creation of Via Oncology, a clinical pathways vendor.

April 15th 2016

Oncology Payment Reform: Payers and Providers Discuss APM and Beyond

Surabhi Dangi-Garimella, PhD

Everyone in healthcare is currently grappling with what payment reform will look like in the coming years, and oncology is no exception. Payers, providers, and health policy experts reviewed ongoing changes in the healthcare system and shared their vision on what the future would look like.

April 14th 2016

Dr Alan Balch on Improving Shared Decision-Making in Cancer Care

Patients and providers often have very different views of goals and values when it comes to treatment, so healthcare could benefit from figuring out how to systematize the shared decision making experience, Alan Balch, PhD, chief executive officer of the National Patient Advocate Foundation, said at the Community Oncology Alliance's 2016 Community Oncology Conference.

April 14th 2016

An Update on the Oncology Medical Home Model at the COA Conference

Surabhi Dangi-Garimella, PhD

Representatives from 3 clinics that successfully participated in the Commission on Cancer accreditation process for the Oncology Medical Home model participated in a panel discussion on the first day of The Community Oncology Conference: Innovation in Cancer Care.

April 14th 2016

Dr Debra Patt Outlines Cancer Care Delivery, Payment Changes

There are a number of models that look at innovating payments and focus on care delivery changes in oncology that are a positive step forward for patients, Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology, said at the Community Oncology Alliance's 2016 Community Oncology Conference.

April 14th 2016

Aligning Reimbursement With Quality: Are We There Yet?

Surabhi Dangi-Garimella, PhD

On the first day of The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida, April 13-15, 2016, oncologists discussed how their practices are coping with the transition toward quality- and value-based reimbursement.

April 14th 2016

Dr Stephen Grubbs Discusses Creating ASCO's Value Framework

Many value assessment frameworks are still in their infancy and while the American Society of Clinical Oncology (ASCO)'s framework is still getting input and being adjusted, it has started an important conversation, Stephen Grubbs, MD, vice president for clinical affairs at ASCO, said at the Community Oncology Alliance's 2016 Community Oncology Conference.

April 13th 2016

ODAC Advises FDA to Wait for Results of TIGER-3 for Rociletinib in NSCLC

Surabhi Dangi-Garimella, PhD

The committee voted 12-1 in favor of delaying approval of the drug and waiting on results from the phase 3 study.

April 13th 2016

Striking the Balance in Prostate Cancer: Active Surveillance Versus Disease Progression

Surabhi Dangi-Garimella, PhD

A new study published in The Journal of Urology has found that active surveillance in prostate cancer patients who might have a low-grade disease has the possibility of disease progression in only a small number of patients.

April 12th 2016

Benefit of Aspirin to Prevent CVD and CRC Upheld by USPSTF

Surabhi Dangi-Garimella, PhD

An updated recommendation by the US Preventive Services Task Force advises the use of low-dose aspirin in adults 50 to 69 years of age, who have an increased risk of cardiovascular disease (CVD) or colorectal cancer (CRC), are not at an increased risk of bleeding, and have a life expectancy of at least 10 years, for the prevention of CVD and CRC.

April 11th 2016

BCL-2 Inhibitor Venetoclax Approved as Second Line for CLL With 17p Deletion

Surabhi Dangi-Garimella, PhD

The approval comes following the review of a phase 2 single-arm trial in 106 patients with chronic lymphocytic leukemia who carried the 17p deletion mutation and who had received at least 1 prior therapy for their condition.

April 11th 2016

Race and Source of Information Influence Cancer Patient's Estimate of Life Expectancy

Surabhi Dangi-Garimella, PhD

A prospective longitudinal study that followed terminally ill cancer patients till their death has found that patients of African American origins had a poorer understanding of their survival than the white patients in the study group.

April 8th 2016

Are FDA Reviewers Concerned About the Value of Clovis Oncology's EGFR Inhibitor Rociletinib?

AJMC Staff

A preliminary briefing document expresses concerns over clinical benefit over existing treatments, safety, and overall risk-benefit of the drug for the subset of lung cancer patients for whom the drug has been developed.

April 8th 2016

5 Takeaways From the NCCN Annual Conference

Surabhi Dangi-Garimella, PhD

The National Comprehensive Cancer Network (NCCN)'s annual conference has traditionally been a platform for NCCN’s Guideline updates. This year's meeting saw much more, with discussions on palliative care, biosimilars, and value in cancer care.

...

100 101 102 103 104 105 106 107 108

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions